Literature DB >> 9700182

Iron-chelation therapy with oral deferiprone--toxicity or lack of efficacy?

K V Kowdley, M M Kaplan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9700182     DOI： 10.1056/NEJM199808133390709

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  9 in total

Review 1.  Clinical research: a tale of two studies.

Authors:  David G Nathan
Journal:  Trans Am Clin Climatol Assoc       Date:  2003

Review 2.  The exochelins of pathogenic mycobacteria: unique, highly potent, lipid- and water-soluble hexadentate iron chelators with multiple potential therapeutic uses.

Authors:  Lawrence D Horwitz; Marcus A Horwitz
Journal:  Antioxid Redox Signal       Date:  2014-06-20       Impact factor: 8.401

3.  Constraints of interest: lessons at the Hospital for Sick Children.

Authors:  R A Phillips; J Hoey
Journal:  CMAJ       Date:  1998-10-20       Impact factor: 8.262

Review 4.  Iron toxicity and chelation therapy.

Authors:  Robert S Britton; Katherine L Leicester; Bruce R Bacon
Journal:  Int J Hematol       Date:  2002-10       Impact factor: 2.490

Review 5.  Deferiprone: a review of its clinical potential in iron overload in beta-thalassaemia major and other transfusion-dependent diseases.

Authors:  J A Barman Balfour; R H Foster
Journal:  Drugs       Date:  1999-09       Impact factor: 9.546

Review 6.  World health dilemmas: Orphan and rare diseases, orphan drugs and orphan patients.

Authors:  Christina N Kontoghiorghe; Nicholas Andreou; Katerina Constantinou; George J Kontoghiorghes
Journal:  World J Methodol       Date:  2014-09-26

Review 7.  Benefits and risks of deferiprone in iron overload in Thalassaemia and other conditions: comparison of epidemiological and therapeutic aspects with deferoxamine.

Authors:  George J Kontoghiorghes; Katia Neocleous; Annita Kolnagou
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

8.  Disposal of iron by a mutant form of lipocalin 2.

Authors:  Jonathan Barasch; Maria Hollmen; Rong Deng; Eldad A Hod; Peter B Rupert; Rebecca J Abergel; Benjamin E Allred; Katherine Xu; Shaun F Darrah; Yared Tekabe; Alan Perlstein; Rebecca Wax; Efrat Bruck; Jacob Stauber; Kaitlyn A Corbin; Charles Buchen; Vesna Slavkovich; Joseph Graziano; Steven L Spitalnik; Guanhu Bao; Roland K Strong; Andong Qiu
Journal:  Nat Commun       Date:  2016-10-31       Impact factor: 14.919

9.  Deferiprone in the treatment of transfusion-dependent thalassemia: a review and perspective.

Authors:  Renzo Galanello
Journal:  Ther Clin Risk Manag       Date:  2007-10       Impact factor: 2.423
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.